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The Dexamethasone Suppression Test in Inpatients 
with Panic Disorder or Agoraphobia with 
Panic Attacks 
Leon Grunhaus, Dolores Tiongco, Roger F. Haskett, and 
John F. Greden 
Introduction 
The hypothalamic-pituitary-adrenal (HPA) axis 
has been meticulously investigated in psychi- 
atric illness, particularly in depression (Sachar 
et al. 1973; Sachar 1975). The Dexamethasone 
Suppression Test (DST) as a measure of the 
integrity of inhibitory feedback loops (Carroll 
et al. 1981; Stokes et al. 1984; Arana et al. 
1985) of the HPA axis has received much at- 
tention. Though some controversy remains (Ar- 
ana et al. 1985), there appears to be a general 
consensus that moderate to severe major de- 
pressive disorder (MDD), particularly in older 
inpatients, will lead to disinhibition of the HPA 
axis in a significant number of patients. On tbe 
other hand, the DST in patients with panic at- 
tacks (PA)-panic disorder (PD) and agorapho- 
bia-has consistently yielded suppression in a 
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vast majority (82%-100%) of cases (Liberman 
et al. 1983; Sheehan et al. 1983; Cottraus and 
Claustrat 1984; Avery et al. 1985; Coryell et al. 
1985; Petterson et al. 1985; Roy-Byrne and Uhde 
1985). These results have been interpreted by 
some authors (Sheehan et al. 1983) as evidence 
of a biological difference in HPA activity be- 
tween patients with MDD and patients with PD 
and agoraphobia. This hypothesis, however, has 
not been tested in inpatients with PD or ago- 
raphobia. To assess HPA function among in- 
patients with PD or agoraphobia with PA, we 
completed a DST during each week of hospi- 
talization; six of the eight patients showed non- 
suppression at least once during the pretreatment 
phase of their hospitalization. 
Methods 
Patients were hospitalized in the Clinical Studies 
Unit (CSU) of the University of Michigan. Our 
standard evaluation (Carroll et al. 198 1) consists 
of a 14-day evaluation period, several clinical, 
family, and structured diagnostic interviews 
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phrenia @ADS) and SADS-Lifetime version 
(SADS-L)] , and a thorough physical evaluation. 
Comprehensive diagnoses follow the Research 
Diagnostic Criteria (RDC) (Spitzer et al. 1975). 
A search in our inpatient records identified 
eight patients, four women and four men aged 
22-58 years, meeting RDC diagnosis of PD or 
agoraphobia with PA during the current episode 
of illness. As stated in the RDC criteria, patients 
can meet these diagnoses only in the absence of 
an affective diagnosis. 
DST and clinical ratings were performed 
weekly by clinicians blind to laboratory data. 
The 17-point Hamilton Rating Scale for Depres- 
sion (HRSD) (Hamilton 1960) was the main 
rating instrument; we also looked at the HRSD 
with the psychic and somatic anxiety ratings 
extracted (the A-HRSD). Criteria for exclusion 
from the study were those recommended by Car- 
roll et al. (1981), Stokes et al. (1984), and Arana 
et al. (1985). Informed consent for participation 
in research was required. 
The 1 -mg DST was conducted at least 3 days 
after admission, using the procedure of Carroll 
et al. (1981). DSTs were considered to be non- 
suppressive if either value (4:00 PM or 1l:OO 
PM) on day 2 was above 5 pg/dl. Patients were 
considered to be nonsuppressors if any pretreat- 
ment DST exceeded the cut-point of 5 p,g/dl. 
Plasma cortisol was assayed using a competitive 
protein-binding assay (Murphy 1967), which was 
standardized for the lower ranges of plasma cor- 
tisol. 
Results 
Figure 1 presents a compilation of the results of 
the serial measurements of HRSD, A-HRSD, 
and postdexamethasone plasma cortisols. Six 
patients showed at least one nonsuppressive DST 
during the first 2 weeks of hospitalization. Only 
one patient had a clear history of depressive 
episodes; interestingly, he was one of the con- 
sistent suppressors. There was no significant 
correlation between HRSD ratings and cortisol 
values (r = 0.06; NS). All but one (patient 1A) 
of the patients were drug-free for at least 1 week 
before treatment was started. 
Response to treatment varied considerably. 
Patient 1A received 7 mg/day of alprazolam with 
poor results. Five patients (2A, 3A, 4A, 6A, 
and 7A) received imipramine, either alone or in 
combination with alprazolam. Three of these 
(3A, 6A, and 7A) showed a good therapeutic 
response, whereas two could only tolerate 75 
mg of imipramine and showed a poor response 
to treatment. One patient (5A) received phe- 
nelzine, 45 mg/day; even though his discharge 
HRSD was high, a 3-month follow-up showed 
complete remission of his PA and agoraphobic 
behavior. The remaining patient (8A) presented 
only phobic symptoms during hospitalization. 
Discussion 
Six of eight cases reported showed nonsuppres- 
sive DSTs, suggesting that agoraphobia and PD 
inpatients have nonsuppressive DSTs more often 
than their outpatient counterparts. This inpa- 
tient/outpatient difference, even though tenta- 
tive because of the small sample studied, raises 
some interesting questions. 
The majority of patients with PA, even those 
with severe symptoms, seldom require hospi- 
talization. There is fairly good evidence to sug- 
gest that whenever hospitalization is necessary, 
the association with depression is high (Bowen 
and Kohut 1979; Dealy et al. 198 1). The rela- 
tionship between PA and MDD is further 
strengthened by recent findings of frequent fam- 
ily history of affective disorder in patients with 
PD and agoraphobia with PA (Bowen and Kohut 
1979; Munjack and Moss 1981; Leckman et al. 
1983). Moreover, 60%-70% of patients with 
these anxiety diagnoses are currently or even- 
tually diagnosed as having MDD as well (Breier 
et al. 1984). 
It is possible, then, that these inpatients with 
PA are showing the HPA abnormality that is 
characteristic of endogenous depression, even 
though they lack sufficient clinical features to 
justify diagnosis of this condition. It may well 
be that these patients should be considered as 
having an affective illness and be treated ac- 
cordingly. In another study (Grunhaus et al. 
1986), we found the rates of DST nonsuppres- 
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Figure 1. Highest postdexamethasone plasma cortisol, Hamilton Depression ratings (HRSD), and adjusted 
HRSD ratio (A-HRSD) ratings in inpatients with panic disorder or agoraphobia with panic attacks. 
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sion to be similar in patients with MDD and 
MDD with simultaneous PA. Thus, when a spe- 
cific diagnosis of depression is associated with 
PA, HPA dysregulation resembles that occur- 
ring in depression. The need for hospitalization 
in patients with PA may be an indicator of a 
more severe form of illness, probably affective 
related, that is associated with DST nonsuppres- 
sion. Support for this hypothesis comes from a 
report of DST results in primary obsessive-com- 
pulsive patients (Insel et al. 1982). Insel et al. 
found DST nonsuppression in 6 of 16 patients 
with obsessive-compulsive disorder; all of the 
nonsuppressors were inpatients and had signif- 
icant ratings for depression, even though none 
of them had depression as a primary diagnosis. 
It may be, then, that HPA dysfunction is a com- 
mon feature of severe forms of psychiatric ill- 
ness characterized by either primary or second- 
ary affective pathology. 
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